Figure 1.

Treatment algorithm for epithelial ovarian cancer.

+/-: with/without; debulking: complete resection (i.e., residual disease=0 cm); BRCA: breast cancer gene; PARPi: poly (ADP-ribose) polymerase inhibitor; PFI: platinum-free interval until relapse; PLD: pegylated liposomal doxorubicin. 1 The goal is complete resection, but surgery is sometimes indicated if only effective cytoreduction (<1 cm of residual disease) is achievable. 2 If intolerance to paclitaxel, alternative regimens should be used ac- cording to preference and tolerability (carboplatin + docetaxel or carboplatin + PLD). 3 Olaparib, niraparib and rucaparib (niraparib and rucaparib are not reimbursed in Belgium yet). 4 In Europe, only rucaparib is licensed by the European Medicines Agencyas a monotherapy for patients with platinum-sensitive disease. 5 For patients who have not received prior therapy with a vascular endothelial growth factor receptor-targeted agent. 6 Participation in clinical trials is in all steps of the flowchart an option.